{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:27:50Z","timestamp":1750228070627,"version":"3.40.5"},"reference-count":20,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.2217\/fon-2023-0620","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:09:00Z","timestamp":1698322140000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated\n            <i>EGFR<\/i>\n            Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"first","affiliation":[{"name":"Hemato-Oncology and Medical Oncology Center, Seoul National University Hospital, Seoul, 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Curie, Institut du Thorax Curie-Montsouris, Paris cedex 05, 75248, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B","family":"Leighl","sequence":"additional","affiliation":[{"name":"Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Sabari","sequence":"additional","affiliation":[{"name":"Medical Oncology, New York University Langone Health, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Rahhali","sequence":"additional","affiliation":[{"name":"Janssen Cilag, \u00cele-de-France, 92787, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio A","family":"Schioppa","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, B-2340, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, B-2340, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sermon","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, B-2340, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor","family":"Chandler","sequence":"additional","affiliation":[{"name":"Evidence Synthesis, Modeling &amp; Communication, Evidera, Waltham, MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[{"name":"Evidence Synthesis, Modeling &amp; Communication, Evidera, London, W6 8BJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhee","family":"Jain","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D, Raritan, NJ 08869, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D, Raritan, NJ 08869, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzy Van","family":"Sanden","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, B-2340, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00868-z"},{"key":"e_1_3_9_3_1","unstructured":"American Lung Association . EGFR and Lung Cancer. www.lung.org\/lung-health-diseases\/lung-disease-lookup\/lung-cancer\/symptoms-diagnosis\/biomarker-testing\/egfr (Accessed 22 March 2022 )."},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.10"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0038-9"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.020"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2083326"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"issue":"6","key":"e_1_3_9_9_1","first-page":"EE274","article-title":"Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy","volume":"25","author":"Vadagam P","year":"2022","unstructured":"Vadagam P, Vanderpoel J, Khan Aet al. Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy. Value in Health. 25(6 Suppl. 1), EE274 (2022).","journal-title":"Value in Health."},{"key":"e_1_3_9_10_1","unstructured":"RYBREVANT\u2122 (amivantamab-vmjw) [package insert]. Janssen Biotech Inc Horsham PA (2021)."},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4761"},{"key":"e_1_3_9_12_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) . NCCN Guidelines V.3.2022 Non-Small Cell Lung Cancer.\u00a9 National Comprehensive Cancer Network Inc. 2022. All rights reserved. www.nccn.org\/ (Accessed 20 February 2023 )."},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9115"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221098398"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.083"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9008"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9007"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(21)02013-X"},{"issue":"6","key":"e_1_3_9_20_1","first-page":"MSR41","article-title":"Matching-Adjusted Indirect Comparison of Amivantamab vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated non-small-cell Lung Cancer","volume":"25","author":"Van Sanden S","year":"2022","unstructured":"Van Sanden S, Rahhali N, Schioppa Cet al. Matching-Adjusted Indirect Comparison of Amivantamab vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated non-small-cell Lung Cancer. Value in Health. 25(6_S1), MSR41 (2022).","journal-title":"Value in Health."},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9126"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:30:46Z","timestamp":1726756246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.2217\/fon-2023-0620"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0620","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}